High hematocrit on TRT: is 54% really the red line?

What did @trtover40 actually say?

The creator's core argument is that men on TRT are too quick to panic over a single elevated hematocrit reading. They say "red blood cells live for about 120 days," which means a high result at week 12 "is often just your body adapting." They also name a specific threshold: 54% hematocrit is the "red line" that requires immediate action. The message is about trend-watching over snapshot-reacting, and calling out hydration, sleep apnea, smoking, dose, and injection frequency as variables that shift the number.

To be fair, this is a more nuanced take than the average TRT content online, which tends to be either recklessly permissive or reflexively alarmed. The creator is trying to build some clinical literacy in their audience, and that intent is worth acknowledging before we pick it apart.

Does the science back this up?

Mostly, yes, but with important caveats. The 120-day red blood cell lifespan figure is textbook physiology and accurate. The concern about erythrocytosis on TRT is well-documented: testosterone stimulates erythropoiesis through EPO and direct bone marrow effects, and elevated hematocrit is the most common adverse effect of TRT, occurring in roughly 11-38% of men depending on the formulation (Bachman et al., 2010, Journal of Clinical Endocrinology and Metabolism).

The 54% threshold the creator cites aligns reasonably with clinical practice. The Endocrine Society's 2018 guidelines suggest withholding or reducing testosterone when hematocrit exceeds 54%, citing increased blood viscosity and theoretical thrombotic risk. The British Society for Sexual Medicine uses a similar cutoff. However, the evidence linking hematocrit elevations in the 50-54% range to actual cardiovascular events in TRT patients is weaker than many clinicians imply (Jones et al., 2011, European Journal of Endocrinology). The association exists in epidemiological data, but causality in a treated hypogonadal population is genuinely unsettled.

What did they get wrong (or right)?

The creator got the 120-day RBC lifespan right. The 54% cutoff is clinically standard. The list of confounding variables, hydration, sleep apnea, smoking, dose, and injection frequency, is accurate and underappreciated. Hemoconcentration from poor hydration alone can artificially push a hematocrit reading up by several percentage points, a fact that almost never appears in TRT content.

Where this gets slippery is the framing around donating blood every three months. The creator implies this is often an overreaction. That may be true for borderline cases, but therapeutic phlebotomy is a legitimate and guideline-supported intervention when hematocrit genuinely trends upward. There is also a real risk in the opposite direction: iron depletion from repeated donations can cause its own problems (Charney et al., 2017, American Journal of Hematology). The creator does not distinguish between a borderline reading that warrants watchful waiting and a persistently elevated one that genuinely needs intervention. That gap matters clinically.

Calling a week-12 reading "just adapting" is also not universally true. Some men stabilize; others do not. Trend data requires multiple readings, not just patience after one.

What should you actually know?

If your hematocrit is elevated on TRT, the first question is whether the test conditions were controlled. Were you well-hydrated? Did you donate blood recently? Do you have untreated sleep apnea? These are legitimate variables, not excuses to ignore a result. A single reading is genuinely insufficient to make permanent protocol decisions, and retesting under consistent conditions is reasonable medicine.

That said, a reading at or above 54% is not something to sit on and trend-watch. The Endocrine Society and the American Urological Association both treat this as an intervention threshold, not a suggestion. If your hematocrit is persistently in the 50-54% range, that deserves a conversation with the clinician managing your protocol, not a TikTok comment section.

The deeper issue is that hematocrit monitoring frequency matters as much as the number itself. The Endocrine Society recommends checking at 3-6 months after initiating or adjusting TRT, then annually. If you are only testing once at week 12, you do not have trend data. You have a data point.

• Retest before making protocol changes, but do not delay if the reading is at or above 54%.
• Untreated obstructive sleep apnea is an independent driver of erythrocytosis and should be ruled out.
• Injection frequency affects peak androgen levels and may influence hematocrit more than total weekly dose.
• Iron stores should be monitored if therapeutic phlebotomy is being used repeatedly.